Analyst Charles Zhu from LifeSci Capital maintains a Buy rating for Mersana Therapeutics, citing promising clinical data for their product XMT-1660 (Emi-Le), favorable safety profile, and strong financial position. The company has also received two FDA Fast Track Designations for their product in specific cancer types.
Mersana Therapeutics, Inc. announced that the FDA has granted Fast Track designation to XMT-1660, a novel treatment for adult patients with advanced or metastatic triple-negative breast cancer (TNBC). This designation aims to expedite the development and review of XMT-1660, which has shown promising anti-tumor effects in preclinical studies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.